Jana Care Aina

Target SDGs

Market Suggested Retail Price

$50.00

Market Suggested Retail Price (Secondary Currency)

1.00

Target Users (Target Impact Group)

Household, Small and Medium-sized Enterprises, Public Sector Agencies

Distributors / Implementing Organizations

The manufacturer distributes his own product, Hospitals like Narayana Health Hospital in Bangalore, India are implementing the product

Competitive Landscape

Direct competitors include PATH: Strip test for gestational diabetes.

Regions

Europe

Countries

India, Malaysia, Singapore

Manufacturing/Building Method

The product is also Mass Produced. The company is headquartered in Boston with an ISO13485 certified manufacturing site in India

Intellectural Property Type

Patent

User Provision Model

Patients can procure the Jana Care Aina from health clinics and hospitals or purchase  it directly from the manufacturer and download the companion app from the Google Play or the Apple Store. The healthcare workers also use the device to directly test patients.

Customers can also request a demo from the manufacturers website

Distributions to Date Status

50,000 patients in India as of February 2017.

Design Specifications

The Jana Care Aina Device is a blood glucometer that uses existing colorimetric test strips and plugs into any smartphone via the headphone jack. Blood readings are communicated to an accompanying mobile app, which allows pre-diabetic users to monitor consistently their glucose levels as well as weight, food intake, and physical activity. The product works with iOs and Android devices.

The Aina device HbA1c test utilizes a method called  boronate affinity. The Aina HbA1c Test Kit consists of test strips, reagents, wash buffers, capillary tubes for collection of samples, and pipette tips. The reagent contains a lysing agent and a blue boronic acid conjugate. When blood is added to the reagent, the erythrocytes are lysed and all hemoglobin precipitates. The boronic acid conjugates binds to the glycosylated hemoglobin. An aliquot of the reaction mixture is applied to the test strip and all the precipitated hemoglobin, conjugate-bound and unbound, remains on top of the filter. Any unbound boronate is removed with the wash buffer. The precipitate is evaluated by measuring the blue (glycosylated hemoglobin) and the red (total hemoglobin) color intensity
respectively with the Aina Device, the ratio between them being proportional to the percentage of the glycosylated hemoglobin in the sample.

The product has the following technical specifications

Dimensions: 79.57 (L) X 36.54 (B) X 16.40 mm (H)

Weight: 0.021kg (without battery), 0.032 kg (with battery)

Power Requirements: 1.5V AAA battery

Safety: Battery powered device, tested for compliance with EN 61010-1, EN 61010-2-101 and RoHS

EMC Emissions/Immunity: Aina Device complies with applicable EMC emission requirements as per EN 61326-1:2013 and EN 61326-2-6:2013

Product Schematics

Technical Support

Users can be supported through the habits App. The user can also visit Jana care's desk support

Replacement Components

Single-use test strips

Lifecycle

The test strips are single-use. Aida device lifecycle is unknown.

Manufacturer Specified Performance Parameters

Goals:

- Early detection for diabetes, pre-diabetes and other chronic diseases

- In point diagnostics and monitoring

- Easy to use

- Low cost

Vetted Performance Status

Method comparison to a YSI 2300 analyzer with 750 patient blood samples shows that the Jana Care Aina conforms with accuracy and repeatability requirements specified by ISO 15197:2013 standard (In vitro diagnostic test systems — Requirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus). Additional test results can be found in the Analytical Performance Summary.

Safety

The device is tested for compliance with EN 61010-1, EN 61010-2-101 and RoHS

It is important to make sure hands and device are clean before use in order to prevent infection.

Complementary Technical Systems

Smartphone, testing strips, the Jana Care Habits app

Academic Research and References

Compliance with regulations

Aina's accuracy meets ISO15197:2013 regulatory standards needed for CE and US FDA approval.

Evaluation methods

Jana Care has conducted trials with Mass General Hospital, the National University Hospital,  Xiangya Hospital, Changsha, China and others.

Other Information

The device also docks with the Aina Station, a point-of-care platform that can sit in a primary care office or clinic to screen patients with the goal of reduce time that patients have to wait for results from a central lab.